AI assistant
Sending…
Immuneering Corp — Director's Dealing 2022
Apr 14, 2022
32973_dirs_2022-04-14_e1fc84b3-d6f3-473f-bc75-dcdcc1d37288.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2022-04-12
Reporting Person: Zeskind Benjamin J. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-04-12 | Class A Common Stock | M | 2000 | $3.01 | Acquired | 2259352 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-04-12 | Stock Option | $3.01 | M | 2000 | Disposed | 2029-12-15 | Class A Common Stock (2000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Common Stock | 894927 | Indirect |
Footnotes
F1: Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.
F2: The option has fully vested and is currently exercisable.
More from Immuneering Corp
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Major Shareholding Notification
2026
Jan 22